Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
Status:
Completed
Trial end date:
2020-08-07
Target enrollment:
Participant gender:
Summary
prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate
safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with
Primary Biliary Cholangitis. A total 36 subjects will be enrolled in a ratio of 1:1:1 to
receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.